The Cancer Vaccine That Could Save Moderna
About this episode
The episode discusses Moderna's transition from a COVID vaccine success to developing an mRNA-based vaccine for skin cancer.
For years, Moderna was a one-hit wonder, a company that bet everything on mRNA, struck gold with a COVID vaccine and then watched its stock crater as the pandemic faded. Now, the company may have found a way to fight skin cancer. An experimental mRNA-based vaccine succeeded in preventing melanoma from returning in high-risk patients, sending drug industry stocks soaring. WSJ’s Xavier Martinez traces Moderna’s wild ride from scrappy startup to the frontier of cancer treatment. Ryan Knutson hosts. Further Listening: - The FDA Commissioner on Vaccines and Public Trust - The Creator of the Record-Setting Covid Vaccine Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
More episodes of The Journal.
- AI Companies Are Buying and Destroying Used Books
- My Monday Morning: Lee Pace
- How the Bond Market Will Affect Your Wallet
- The Cardboard Box Economy Is Breaking Down
- How Big Food Is Navigating the GLP-1 Era
- Inside the U.S. Deal to Get Venezuela’s Oil
Explore listener stats, chart rankings, contacts and more on the The Journal. podcast page.